Metals and the liver

Current Opinion in Gastroenterology

Volumn 28, Issue 3, 2012, Pages 217-222

  Maxwell, Kathryn L ^a   Kowdley, Kris V ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

cirrhosis; ferroportin; hemochromatosis; hepcidin; Wilson disease

Indexed keywords

CERULOPLASMIN; DEFERASIROX; DEFERIPRONE; FERRITIN; FERROPORTIN; HEPCIDIN; HFE PROTEIN; IRON; PENICILLAMINE; TRIENTINE; ZINC DERIVATIVE;

ARTHRITIS; CARDIOMYOPATHY; DIABETES MELLITUS; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENETICS; GENOTYPE; HEMOCHROMATOSIS; HOMOZYGOTE; HUMAN; HYPERPIGMENTATION; HYPOGONADISM; IRON OVERLOAD; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PHLEBOTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; WILSON DISEASE;

ADENOSINE TRIPHOSPHATASES; CATION TRANSPORT PROTEINS; COPPER; FEMALE; FERRITINS; GENOTYPE; HEMOCHROMATOSIS; HEPATOLENTICULAR DEGENERATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MUTATION; PHLEBOTOMY;

EID: 84859885023     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283521d82     Document Type: Review

References (35)

1. Pietrangelo A. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53:3-22.
2. Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1:191-200. (Pubitemid 43960600)
3. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306:2090-2093. (Pubitemid 40007660)
4. Sangwaiya A, Manglam V, Busbridge M, et al. Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis. Eur J Gastroenterol Hepatol 2011; 23:721-724.
5. Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328-343.
6. Mura C, Raguenes O, Fé rec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93:2502-2505.
7. Cheng R, Barton JC, Morrison ED, et al. Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes. J Clin Gastroenterol 2009; 43:569-573.
8. Aguilar-Martinez P, Grandchamp B, Cunat S, et al. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica 2011; 96:507-514.
9. Carneiro AA, Fernandes JP, de Araujo DB, et al. Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptometry. Magn Reson Med 2005; 54:122-128. (Pubitemid 40898404)
10. Maliken BD, Avrin WF, Nelson JE, et al. Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin. Ann Hepatol 2012; 11:77-84.
11. Elmberg M, Hultcrantz R, Simard JF, et al. Risk of ischaemic heart disease and cardiomyopathy in patients with haemochromatosis in their first-degree relatives: a nationwide population-based study. J Intern Med 2011. [Epub ahead of print]
12. Allen KJ, Bertalli NA, Osborne NJ, et al. HFE cys282tyr homozygotes with serum ferritin concentrations below 1000mg/L are at low risk of hemochromatosis. Hepatology 2010; 52:925-933.
13. Jin F, Qu L, Shen X. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a metaanalysis. J Exp Clin Cancer Res 2010; 29:1-8.
14. Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. Risk of cancer by transferrin saturation and haemochromatosis genotype: population-based study and meta-analysis. J Intern Med 2012; 271:51-63.
15. Pietrangelo A. Iron chelation beyond transfusion iron overload. Ann J Hematol 2007; 21:101-104.
16. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 2003; 123:952-953. (Pubitemid 37533309)
17. Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010; 52:1671-1679.
18. Griffiths WJ, Mayr R, McFarlane I, et al. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by novel ferroportin mutation. Hepatology 2010; 51:788-795.
19. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32:131-138. (Pubitemid 38147710)
20. Pietrangelo A, Caleffi A, Corrandini E. Non-HFE hepatic iron overload. Semin Liver Dis 2011; 31:302-318.
21. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systemic metaanalysis of clinical and molecular findings. J Hepatol 2010; 53:941-949. Classical ferroportin disease is associated with less fibrosis on liver biopsy when compared with HFE hemochromatosis. Nonclassical ferroportin disease has higher risk of fibrosis compared with HFE hemochromatosis.
22. Beaton M, Guyader D, Deugnier Y, et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002; 36:673-678. (Pubitemid 34977178)
23. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995; 9:210-217.
24. Shah AB, Chernov I, Zhang HT, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997; 61:317-328. (Pubitemid 27382307)
25. Kim EK, Yoo OJ, Song KY, et al. Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease. Hum Mutat 1998; 11:275-278. (Pubitemid 28177868)
26. Nanji MS, Nguyen VT, Kawasoe JH, et al. Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 1997; 60:1423-1429. (Pubitemid 27258074)
27. Roberts EA, Schilsky MI. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089-2111. (Pubitemid 351945575)
28. Rosencrantz R, Schilsky M. Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis 2011; 31:245-259.
29. Nicastro E, Ranucci G, Vajro P, et al. Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology 2010; 52:1948-1956.
30. Lee BH, Kim JH, Lee SY, et al. Distinct clinical courses according to presenting phenotypes and their correlations to ATP7B mutations in a large Wilson's disease cohort. Liver Int 2011; 31:831-839.
31. Wong RJ, Gish R, Schilsky M, Frenette C. A clinical assessment of Wilson disease in patients with concurrent liver disease. J Clin Gastroenterol 2011; 45:267-273.
32. Linder MC, Hazegh-Azam M. Copper biochemistry and molecular biology. Am J Clin Nutr 1996; 63:797S-811S. (Pubitemid 26126602)
33. Podgaetz E, Chan C. Liver transplantation for Wilson's disease: our experience with review of the literature. Ann Hepatol 2003; 2:131-134.
34. Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011; 140:1189-1198.
35. Arnon R, Annunziato R, Schilsky M, et al. Liver transplantation for children with Wilson disease: comparison of outcomes between children and adults. Clin Transplant 2011; 25:E52-E60.